Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-000713-32
    Sponsor's Protocol Code Number:CAEL-101-302
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-06-01
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2020-000713-32
    A.3Full title of the trial
    A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis
    Studio di Fase 3, in doppio cieco, multicentrico per valutare l’efficacia e la sicurezza di CAEL-101 e del trattamento per discrasia plasmacellulare rispetto a placebo e al trattamento per discrasia plasmacellulare in pazienti naïve al trattamento per discrasia plasmacellulare con amiloidosi AL in stadio IIIa Mayo
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis.
    Uno studio in doppio cieco per valutare l'efficacia e la sicurezza di CAEL-101 in pazienti con amiloidosi AL.
    A.3.2Name or abbreviated title of the trial where available
    CAEL-101-302
    CAEL-101-302
    A.4.1Sponsor's protocol code numberCAEL-101-302
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04512235
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCaelum Biosciences, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCaelum Biosciences, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCaelum Biosciences, Inc.
    B.5.2Functional name of contact pointEileen Daniel
    B.5.3 Address:
    B.5.3.1Street Address1200 Florence-Columbus Road #208
    B.5.3.2Town/ cityBordentown, New Jersey
    B.5.3.3Post code08505-4200
    B.5.3.4CountryUnited States
    B.5.4Telephone number0016093373010
    B.5.6E-mailEDaniel@caelumbio.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/19/2222
    D.3 Description of the IMP
    D.3.1Product nameCAEL-101
    D.3.2Product code [CAEL-101]
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeCAEL-101
    D.3.9.3Other descriptive nameCh11-1F4 (NSC-711516)
    D.3.9.4EV Substance CodeSUB198710
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    stage IIIa cardiac AL amyloidosis
    amiloidosi cardiaca di stadio IIIa AL
    E.1.1.1Medical condition in easily understood language
    Cardiac amyloidosis is a disorder caused by deposits of an abnormal protein (amyloid) in the heart tissue. These deposits make it hard for the heart to work properly.
    L'amiloidosi cardiaca è una malattia causata da depositi di una proteina anormale (amiloide) nel tessuto cardiaco. Questi depositi rendono difficile il corretto funzionamento del cuore.
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level SOC
    E.1.2Classification code 10007541
    E.1.2Term Cardiac disorders
    E.1.2System Organ Class 10007541 - Cardiac disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objectives are:
    • To determine if CAEL-101 and treatment for plasma cell dyscrasia improves overall survival in Mayo stage IIIa AL amyloidosis patients who are treatment naïve compared to treatment for plasma cell dyscrasia alone
    • To evaluate the safety and tolerability of CAEL-101 in combination with treatment for plasma cell dyscrasia
    Gli obiettivi primari sono:

    • Stabilire se CAEL-101 e il trattamento per discrasia plasmacellulare migliori la sopravvivenza complessiva nei pazienti con amiloidosi AL in stadio IIIa Mayo, che sono naïve al trattamento rispetto al trattamento per discrasia plasmacellulare in monoterapia

    • Valutare la sicurezza e la tollerabilità di CAEL-101 in combinazione con il trattamento per discrasia plasmacellulare
    E.2.2Secondary objectives of the trial
    The key secondary objectives in this study are:
    • To assess functional improvement as measured by the distance walked in the six-minute walk test (6MWT)
    • To assess quality of life as measured by the Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)
    • To assess quality of life as measured by the Short Form 36 version 2 Physical Component Score (SF-36 v2® PCS)
    • To assess cardiac improvement as measured by percent Global Longitudinal Strain (GLS%)
    I principali obiettivi secondari di questo studio sono:

    • Valutare il miglioramento funzionale, misurato mediante la distanza percorsa nel Test del cammino di sei minuti (6MWT)

    • Valutare la qualità della vita, misurata tramite il Punteggio complessivo del
    Questionario di Kansas City sulla miocardiopatia (KCCQ-OS)

    • Valutare la qualità della vita, misurata tramite il Questionario breve a 36 voci, versione
    2 del Punteggio della componente fisica (SF-36 v2 PCS)

    • Valutare il miglioramento cardiaco, misurato in base alla percentuale dello strain longitudinale globale (GLS%)
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Be able to and provide written informed consent and be willing and able to comply with all study procedures
    2. Adult, 18 years and older
    3. AL amyloidosis stage IIIa based on the 2013 European Modification of the 2004 Standard Mayo Clinic Staging in patients with advanced cardiac involvement (Wechalekar 2013, Dispenzieri 2004) (See Table 2.) at the time of Screening
    4. Measurable hematologic disease at Screening as defined by at least one of the following:
    a. dFLC > 4 mg/dL or
    b. iFLC > 4 mg/dL with abnormal ratio or
    c. SPEP m-spike > 0.5 g/dL
    5. Histopathological diagnosis of amyloidosis based on polarizing light microscopy of green bi-refringent material in Congo red stained tissue specimens AND confirmation of AL derived amyloid deposits by at least one of the following:
    a. Immunohistochemistry or
    b. Mass spectrometry or
    c. Characteristic electron microscopy appearance
    6. Cardiac involvement as defined by:
    a. Documented clinical signs and symptoms supportive of a diagnosis of heart failure in the setting of a confirmed diagnosis of AL amyloidosis in the absence of an alternative explanation for heart failure
    AND
    b. At least one of the following:
    i. Endomyocardial biopsy demonstrating AL cardiac amyloidosis or
    ii. Echocardiogram demonstrating a mean left ventricular wall thickness (calculated as [IVSd+LPWd]/2) of > 12 mm at diastole in the absence of other causes (e.g., severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening or
    iii. Cardiac MRI with gadolinium contrast agent diagnostic of cardiac amyloidosis
    7. NT-proBNP = 650 and = 8500 ng/L
    8. Planned first-line treatment for plasma cell dyscrasia is a CyBorD-based regimen administered as SoC (Section 6.2.4).
    9. Adequate bone marrow reserve and hepatic function as demonstrated by:
    a. Absolute neutrophil count = 1.0 x 109/L
    b. Platelet count = 75 x 109/L
    c. Hemoglobin = 9 g/dL
    d. Total direct bilirubin = 2 times the upper limit of normal (x ULN) unless due to Gilbert’s syndrome.
    e. AST = 3 x ULN
    f. ALT = 3 x ULN
    g. ALP = 5 x ULN (except for patients with hepatomegaly and isozymes specific to liver, rather than bone)
    10. WOCBP must have a negative pregnancy test during Screening and must agree to use highly effective physician approved contraception (Section 6.9) from Screening to at least 5 months following the last study drug administration or 12 months following the last dose of her PCD therapy, whichever is longer
    11. Men must be surgically sterile or must agree to use effective physician approved contraception (Section 6.9) and refrain from donating sperm from Screening to at least 5 months following the last study drug administration or 12 months following the last dose of his PCD therapy, whichever is longer
    1. Essere in grado di fornire e fornire il consenso informato scritto ed essere disposto e in grado di attenersi alle procedure dello studio
    2. Adulto, di età pari o superiore a 18 anni
    3. Amiloidosi AL in stadio IIIa in base alla Modifica europea del 2013 della Stadiazione standard della Mayo Clinic del 2004 in pazienti con coinvolgimento cardiaco avanzato (Wechalekar 2013, Dispenzieri 2004) (Vedere Tabella 2.) al momento dello Screening
    4. Malattia ematologica misurabile allo Screening come definita da almeno una delle seguenti caratteristiche:
    a. dFLC >4 mg/dl oppure
    b. iFLC >4 mg/dl, con rapporto anomalo oppure
    c. picco M dell’elettroforesi delle proteine sieriche (SPEP m-spike) >0,5 g/dl
    5. Diagnosi istopatologica di amiloidosi basata su microscopia in luce polarizzata di materiale verde birifrangente in campioni di tessuto colorati con rosso Congo E depositi di amiloide AL confermati da almeno una delle seguenti tecniche:
    6. Coinvolgimento cardiaco, come definito da:
    a. Segni e sintomi clinici documentati a supporto di una diagnosi di insufficienza cardiaca nel contesto di una diagnosi confermata di amiloidosi AL, in assenza di una spiegazione alternativa per insufficienza cardiaca
    E
    b. Almeno una delle seguenti circostanze:
    i. Biopsia endomiocardica che dimostri la presenza di amiloidosi AL cardiaca oppure
    ii. Ecocardiogramma che dimostri uno spessore medio della parete ventricolare sinistra (calcolato come [IVSd+LPWd]/2) >12 mm in diastole in assenza di altre cause (ad es., ipertensione grave, stenosi aortica), che potrebbero spiegare adeguatamente il grado di ispessimento della parete oppure
    iii. RMI cardiaca con mezzo di contrasto gadolinio per la diagnosi di amiloidosi cardiaca
    7. NT-proBNP = 650 - = 8500 ng/L
    8. Il trattamento di prima linea previsto per discrasia plasmacellulare è una terapia basata su ciclofosfamide, bortezomib e desametasone (CyBorD) somministrata come standard di cura (SoC).
    9. Riserva di midollo osseo e funzionalità epatica e renale adeguate, come dimostrato da:
    a. Conta assoluta dei neutrofili =1,0 x 10 9 /l
    b. Conta piastrinica =75 x 10 9 /l
    c. Emoglobina =9 g/dl
    d. Bilirubina diretta totale =2 volte il limite superiore della normalità (x ULN) eccetto che se dovuta a sindrome di Gilbert.
    e. AST =3 x ULN
    f. ALT =3 x ULN
    g. ALP =5 x ULN (eccetto per i pazienti con epatomegalia e isoenzimi a livello del fegato, anziché del tessuto osseo)
    10. Le donne in età fertile (WOCBP) devono presentare un test di gravidanza negativo durante lo Screening e devono accettare di utilizzare un metodo di controllo delle nascite altamente efficace approvato dal medico dal momento dello Screening fino ad almeno 5 mesi dopo l’ultima somministrazione del farmaco dello studio o fino a 12 mesi dopo l’ultima dose della loro terapia per PCD, a seconda di quale sia il periodo più lungo.
    a. Immunoistochimica oppure
    b. Spettrometria di massa oppure
    c. Aspetto caratteristico di microscopia elettronica
    11. Gli uomini devono essere chirurgicamente sterili oppure devono accettare di utilizzare un metodo di controllo delle nascite efficace approvato dal medico e astenersi dal donare sperma dal momento dello Screening fino ad almeno 5 mesi dopo l’ultima somministrazione del farmaco dello studio o fino a 12 mesi dopo l’ultima dose della loro terapia per PCD, a seconda di quale sia il periodo più lungo.
    E.4Principal exclusion criteria
    1. Have any other form of amyloidosis other than AL amyloidosis
    2. Received prior therapy for AL amyloidosis or multiple myeloma. A maximum exposure of 160 mg dexamethasone (or equivalent corticosteroid) since diagnosis of AL amyloidosis and prior to randomization is allowed.
    3. Meets the IMWG definition of multiple myeloma or POEMS syndrome (Appendix A)
    4. Have supine systolic blood pressure < 90 mmHg or symptomatic orthostatic hypotension, defined as a decrease in systolic blood pressure upon standing of > 30 mmHg despite medical management (e.g., midodrine, fludrocortisones) in the absence of volume depletion
    5. Taking prednisone or its equivalent > 10 mg/day
    6. Taking doxycycline
    7. Receiving dialysis
    8. Planned stem cell transplant during the first 6 months of protocol therapy. Stem cell collection during the protocol therapy is permitted.
    9. Have had myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias within 6 months prior to screening or percutaneous cardiac intervention withrecent stent or coronary artery bypass grafting within 4 months prior to screening. Exacerbation of chronic condition or new acute condition will require discussion and approval by the Medical Monitor.
    10. LVEF is < 40% by echocardiogram at Screening per site cardiology interpretation
    11. Have severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area < 1.0 cm2) or severe congenital heart disease
    12. Have history of sustained ventricular tachycardia or aborted ventricular fibrillation or a history of atrioventricular nodal or sinoatrial nodal dysfunction for which a pacemaker/implantable cardioverter-defibrillator (ICD) is indicated but not placed. (Patients who do have a pacemaker or ICD are allowed in the study.)
    13. QT corrected by Fridericia (QTcF) is > 500 msec on Screening ECG as measured and corrected by the core lab. Patients who have a pacemaker may be included regardless of calculated QTc interval.
    14. There is evidence of acute ischemia or active conduction system abnormalities with the exception of any of the following:
    a. First degree atrioventricular block
    b. Second degree atrioventricular block Type 1 (Mobitz Type 1/Wenckebach type)
    c. Right or left bundle branch block
    d. Atrial fibrillation with a controlled ventricular rate. (An uncontrolled ventricular rate [i.e., > 110 beats per minute] determined by an average of three beats in lead II or representative beats in lead II is not allowed)
    15. Have had major surgery within 4 weeks of randomization or is planning major surgery during the study. Patients with surgical procedures conducted under local anesthesia may participate
    16. There is active malignancy (including lymphoma) with the exception of any of the following:
    a. Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer
    b. Adequately treated stage I cancer from which the patient is currently in remission and has been in remission for > 2 years
    c. Low-risk prostate cancer with Gleason score < 7 and prostate-specific antigen < 10 mg/mL
    d. Other localized and/or low risk malignancies may be permitted with Medical Monitor approval.
    1. Qualsiasi altra forma di amiloidosi diversa da amiloidosi AL
    2. Pazienti che abbiano ricevuto precedente terapia per amiloidosi AL o mieloma multiplo. Un’esposizione massima di 160 mg di desametasone (o corticosteroide equivalente) dal momento della diagnosi di amiloidosi AL e prima della randomizzazione è consentita.
    3. Soddisfare la definizione del Gruppo di lavoro internazionale per il mieloma (IMWG) di mieloma multiplo o sindrome di POEMS ((polineuropatia, organomegalia, endocrinopatia, proteina M e alterazioni cutanee) (Appendice A)
    4. Pressione arteriosa sistolica in posizione supina <90 mmHg o ipotensione ortostatica sintomatica, definita come una diminuzione della pressione arteriosa sistolica in posizione eretta di >30 mmHg nonostante la gestione medica (ad es., midodrina, fludrocortisone) in assenza di deplezione del volume
    5. Assunzione di prednisone o suo equivalente >10 mg/giorno
    6. Assunzione di doxiciclina
    7. Essere sottoposti a dialisi
    8. Trapianto di cellule staminali previsto durante i primi 6 mesi di terapia del protocollo. La raccolta di cellule staminali durante la terapia del protocollo è consentita.
    9. Avere avuto infarto del miocardio, angina non controllata, aritmie ventricolari gravi non controllate nei 6 mesi precedenti lo Screening o intervento cardiaco percutaneo con stent recente o innesto di bypass arterio-coronarico nei 4 mesi precedenti lo Screening. L’aggravamento di una condizione cronica o una nuova condizione acuta richiederà la discussione e l’approvazione da parte del responsabile del monitoraggio dello studio.
    10. LVEF <40% mediante ecocardiogramma allo Screening come da interpretazione effettuata dalla cardiologia del centro
    11. Avere una grave stenosi valvolare (ad es., stenosi aortica o mitrale con un’area valvolare <1,0 cm2) o grave malattia cardiaca congenita
    12. Avere anamnesi di tachicardia ventricolare sostenuta, o fibrillazione ventricolare abortita o anamnesi di disfunzione del nodo atrioventricolare o di disfunzione del nodosenoatriale per le quali un pacemaker/defibrillatore cardiaco impiantabile (ICD) è indicato, ma non è stato impiantato. (I pazienti che hanno un pacemaker o un ICD sono ammessi nello studio.)
    13. Intervallo QT corretto secondo la formula di Fridericia (QTcF) >500 msec. mediante ECG allo Screening secondo la misurazione e la correzione del laboratorio centrale. I pazienti che hanno un pacemaker possono essere inclusi, indipendentemente dall’intervallo QTc calcolato.
    14. Evidenza di ischemia acuta o anomalie attive del sistema di conduzione ad eccezione di una qualsiasi delle seguenti circostanze:
    a. Blocco atrioventricolare di primo grado
    b. Blocco atrioventricolare di secondo grado di tipo 1 (di tipo Mobitz 1/Wenckebach)
    c. Blocco di branca destra o sinistra
    d. Fibrillazione atriale con una frequenza ventricolare controllata. (Una frequenza ventricolare non controllata [ovvero, >110 battiti al minuto] determinata da una media di tre battiti in derivazione II o di battiti rappresentativi in derivazione II non è consentita)
    15. Avere subito un intervento chirurgico maggiore nelle 4 settimane prima della randomizzazione o avere in programma un intervento chirurgico maggiore durante lo studio. I pazienti con procedure chirurgiche eseguite in anestesia locale possono partecipare
    16. Presenza di neoplasia attiva (compreso il linfoma) ad eccezione di uno qualsiasi dei seguenti tumori:
    a. Carcinoma basocellulare adeguatamente trattato, carcinoma a cellule squamose, o carcinoma in situ della cervice
    b. Tumore adeguatamente trattato in stadio I-III, dal quale il paziente è attualmente in remissione, dopo essere stato in remissione per >2 anni
    c. Tumore alla prostata a basso rischio con punteggio di Gleason <7 e antigene prostatico specifico <10 mg/ml
    d. Altri tumori maligni localizzati e/o a basso rischio possono essere consentiti con l’approvazione del Monitor dello studio.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is overall survival and will be assessed as the time from first dose of study drug to the date of death. Patients living at the end of the study will be censored at their last known date alive. Patients who discontinue study treatment or the study prematurely will be included in the analysis (even if after discontinuation of study treatment or the study) using the death date or censoring time point, as appropriate.
    L’endpoint di efficacia primario è la sopravvivenza complessiva e sarà valutato dal momento della prima dose di farmaco dello studio fino alla data del decesso. I pazienti che sono vivi alla fine dello studio saranno censiti all’ultimo giorno di vita noto. I pazienti che interrompono il trattamento dello studio o lo studio anticipatamente saranno inclusi nell’analisi (anche se dopo l’interruzione del trattamento in studio o lo studio) utilizzando la data di decesso o il punto temporale del censimento, a seconda dei casi.
    E.5.1.1Timepoint(s) of evaluation of this end point
    End of Treatment (EoT) and Follow-up every 12 weeks thereafter. The
    primary endpoint is also evaluated during the Treatment Period.
    Fine del trattamento e follow-up ogni 12 settimane successive, L'endpoint primario viene inoltre valutato durante il periodo di trattamento.
    E.5.2Secondary end point(s)
    The four key secondary efficacy endpoints are:
    • Changes from baseline to Week 50 in the 6MWT distance
    • Changes from baseline to Week 50 in the KCCQ-OS
    • Changes from baseline to Week 50 in the SF-36 v2 PCS
    • Changes from baseline to Week 50 in GLS%
    I quattro principali endpoint secondari di efficacia sono i seguenti:

    • Variazioni dal basale alla Settimana 50 nella distanza 6MWT
    • Variazioni dal basale alla Settimana 50 nel KCCQ-OS
    • Variazioni dal basale alla Settimana 50 nel SF-36 v2 PCS
    • Variazioni rispetto al basale alla Settimana 50 nello GLS%
    E.5.2.1Timepoint(s) of evaluation of this end point
    6MWT, KCCQ-QS & SF-36: Weeks 1, 14, 26, 38 & 50. GLS% (echocardiogram): Screening (Week -4 to 0), Weeks 14, 26 & 50.
    6MWT, KCCQ-QS & SF-36: Weeks 1, 14, 26, 38 & 50. GLS% (echocardiogram): Screening (Week -4 to 0), Weeks 14, 26 & 50
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA30
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Israel
    Japan
    Russian Federation
    United States
    Austria
    Belgium
    France
    Germany
    Italy
    Poland
    Spain
    United Kingdom
    Greece
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The study will be considered complete at the time when the expected number of deaths have been observed, the last surviving patient to start study drug completes at least 50 weeks of treatment or Sponsor decision to terminate the study, whichever comes first.
    Lo studio sarà considerato completo nel momento in cui il numero atteso di decessi sarà stato osservato, l'ultimo paziente sopravvissuto che inizierà il farmaco in studio avrà completato almeno 50 settimane di trattamento o la decisione del Promotere di terminare lo studio, a seconda dell'evento che si verifica per primo.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 160
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 107
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state2
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 76
    F.4.2.2In the whole clinical trial 267
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients who are still receiving treatment with study drug when the
    study is complete may be eligible for enrollment into an open-label,
    extension study of CAEL-101. Patients enrolling into the extension
    study will complete all assessments required at the 14-day EOT visit.
    Patients randomized to placebo in this study will be permitted to enroll
    in extension study and will start CAEL-101 in that trial.
    Pazienti che stanno ancora ricevendo il trattamento con il farmaco in studio quando il
    lo studio è completo può essere idoneo per l'iscrizione in un open-label,
    studio di estensione di CAEL-101. Pazienti che si iscrivono all'estensione
    studio completerà tutte le valutazioni richieste alla visita EOT di 14 giorni.
    I pazienti randomizzati al placebo in questo studio potranno arruolarsi
    in studio di estensione e avvierà CAEL-101 in tale studio.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-12-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-11-17
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 05:15:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA